首页 > 最新文献

Advances in respiratory medicine最新文献

英文 中文
COVID-19 Acute Respiratory Distress Syndrome: Treatment with Helmet CPAP in Respiratory Intermediate Care Unit by Pulmonologists in the Three Italian Pandemic Waves. 新冠肺炎急性呼吸窘迫综合征:肺科医生在三次意大利大流行病浪潮中在呼吸中间监护室使用头盔CPAP治疗。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-09-20 DOI: 10.3390/arm91050030
Martina Piluso, Clarissa Ferrari, Silvia Pagani, Pierfranco Usai, Stefania Raschi, Luca Parachini, Elisa Oggionni, Chiara Melacini, Francesca D'Arcangelo, Roberta Cattaneo, Cristiano Bonacina, Monica Bernareggi, Serena Bencini, Marta Nadalin, Mara Borelli, Roberto Bellini, Maria Chiara Salandini, Paolo Scarpazza

COVID-19 Acute Respiratory Distress Syndrome (CARDS) is the most serious complication of COVID-19. The SARS-CoV-2 outbreaks rapidly saturated intensive care unit (ICU), forcing the application of non-invasive respiratory support (NIRS) in respiratory intermediate care unit (RICU). The primary aim of this study is to compare the patients' clinical characteristics and outcomes (Helmet-Continuous Positive Airway Pressure (H-CPAP) success/failure and survival/death). The secondary aim is to evaluate and detect the main predictors of H-CPAP success and survival/death. A total of 515 patients were enrolled in our observational prospective study based on CARDS developed in RICU during the three Italian pandemic waves. All selected patients were treated with H-CPAP. The worst ratio of arterial partial pressure of oxygen (PaO2) and fraction of inspired oxygen (FiO2) PaO2/FiO2 during H-CPAP stratified the subjects into mild, moderate and severe CARDS. H-CPAP success has increased during the three waves (62%, 69% and 77%, respectively) and the mortality rate has decreased (28%, 21% and 13%). H-CPAP success/failure and survival/death were related to the PaO2/FiO2 (worst score) ratio in H-CPAP and to steroids' administration. D-dimer at admission, FiO2 and positive end expiratory pressure (PEEP) were also associated with H-CPAP success. Our study suggests good outcomes with H-CPAP in CARDS in RICU. A widespread use of steroids could play a role.

新冠肺炎急性呼吸窘迫综合征(CARDS)是新冠肺炎最严重的并发症。严重急性呼吸系统综合征冠状病毒2型疫情迅速使重症监护室(ICU)饱和,迫使无创呼吸支持(NIRS)在呼吸中间监护室(RICU)中应用。本研究的主要目的是比较患者的临床特征和结果(头盔持续气道正压通气(H-CPAP)的成功/失败和生存/死亡)。次要目的是评估和检测H-CPAP成功和生存/死亡的主要预测因素。根据意大利三波疫情期间RICU开发的CARDS,共有515名患者参与了我们的观察性前瞻性研究。所有入选患者均接受H-CPAP治疗。H-CPAP期间动脉血氧分压(PaO2)和吸入氧分数(FiO2)的最差比率PaO2/FiO2将受试者分为轻度、中度和重度CARDS。H-CPAP的成功率在三波中分别增加了62%、69%和77%,死亡率下降了28%、21%和13%。H-CPAP的成功/失败和生存/死亡与H-CPAP中的PaO2/FiO2(最差分数)比率和类固醇的给药有关。入院时的D-二聚体、FiO2和呼气末正压(PEEP)也与H-CPAP的成功相关。我们的研究表明H-CPAP在RICU的CARDS中有良好的效果。类固醇的广泛使用可能起到一定作用。
{"title":"COVID-19 Acute Respiratory Distress Syndrome: Treatment with Helmet CPAP in Respiratory Intermediate Care Unit by Pulmonologists in the Three Italian Pandemic Waves.","authors":"Martina Piluso,&nbsp;Clarissa Ferrari,&nbsp;Silvia Pagani,&nbsp;Pierfranco Usai,&nbsp;Stefania Raschi,&nbsp;Luca Parachini,&nbsp;Elisa Oggionni,&nbsp;Chiara Melacini,&nbsp;Francesca D'Arcangelo,&nbsp;Roberta Cattaneo,&nbsp;Cristiano Bonacina,&nbsp;Monica Bernareggi,&nbsp;Serena Bencini,&nbsp;Marta Nadalin,&nbsp;Mara Borelli,&nbsp;Roberto Bellini,&nbsp;Maria Chiara Salandini,&nbsp;Paolo Scarpazza","doi":"10.3390/arm91050030","DOIUrl":"https://doi.org/10.3390/arm91050030","url":null,"abstract":"<p><p>COVID-19 Acute Respiratory Distress Syndrome (CARDS) is the most serious complication of COVID-19. The SARS-CoV-2 outbreaks rapidly saturated intensive care unit (ICU), forcing the application of non-invasive respiratory support (NIRS) in respiratory intermediate care unit (RICU). The primary aim of this study is to compare the patients' clinical characteristics and outcomes (Helmet-Continuous Positive Airway Pressure (H-CPAP) success/failure and survival/death). The secondary aim is to evaluate and detect the main predictors of H-CPAP success and survival/death. A total of 515 patients were enrolled in our observational prospective study based on CARDS developed in RICU during the three Italian pandemic waves. All selected patients were treated with H-CPAP. The worst ratio of arterial partial pressure of oxygen (PaO<sub>2</sub>) and fraction of inspired oxygen (FiO<sub>2</sub>) PaO<sub>2</sub>/FiO<sub>2</sub> during H-CPAP stratified the subjects into mild, moderate and severe CARDS. H-CPAP success has increased during the three waves (62%, 69% and 77%, respectively) and the mortality rate has decreased (28%, 21% and 13%). H-CPAP success/failure and survival/death were related to the PaO<sub>2</sub>/FiO<sub>2</sub> (worst score) ratio in H-CPAP and to steroids' administration. D-dimer at admission, FiO<sub>2</sub> and positive end expiratory pressure (PEEP) were also associated with H-CPAP success. Our study suggests good outcomes with H-CPAP in CARDS in RICU. A widespread use of steroids could play a role.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 5","pages":"383-396"},"PeriodicalIF":1.8,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41096122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Constrained Disorder Principle Accounts for the Variability That Characterizes Breathing: A Method for Treating Chronic Respiratory Diseases and Improving Mechanical Ventilation. 限制性障碍原理解释了呼吸的变异性:一种治疗慢性呼吸系统疾病和改善机械通气的方法。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-09-09 DOI: 10.3390/arm91050028
Ofek Adar, Adi Hollander, Yaron Ilan

Variability characterizes breathing, cellular respiration, and the underlying quantum effects. Variability serves as a mechanism for coping with changing environments; however, this hypothesis does not explain why many of the variable phenomena of respiration manifest randomness. According to the constrained disorder principle (CDP), living organisms are defined by their inherent disorder bounded by variable boundaries. The present paper describes the mechanisms of breathing and cellular respiration, focusing on their inherent variability. It defines how the CDP accounts for the variability and randomness in breathing and respiration. It also provides a scheme for the potential role of respiration variability in the energy balance in biological systems. The paper describes the option of using CDP-based artificial intelligence platforms to augment the respiratory process's efficiency, correct malfunctions, and treat disorders associated with the respiratory system.

变异性是呼吸、细胞呼吸和潜在量子效应的特征。可变性是应对不断变化的环境的一种机制;然而,这一假设并不能解释为什么呼吸的许多可变现象表现出随机性。根据约束无序原理(CDP),生物体是由其固有的无序定义的,这些无序以可变的边界为界。本文介绍了呼吸和细胞呼吸的机制,重点介绍了它们的内在变异性。它定义了CDP如何解释呼吸和呼吸的可变性和随机性。它还为呼吸变异性在生物系统能量平衡中的潜在作用提供了一个方案。本文描述了使用基于CDP的人工智能平台来提高呼吸过程的效率、纠正故障和治疗与呼吸系统相关的疾病的选项。
{"title":"The Constrained Disorder Principle Accounts for the Variability That Characterizes Breathing: A Method for Treating Chronic Respiratory Diseases and Improving Mechanical Ventilation.","authors":"Ofek Adar,&nbsp;Adi Hollander,&nbsp;Yaron Ilan","doi":"10.3390/arm91050028","DOIUrl":"https://doi.org/10.3390/arm91050028","url":null,"abstract":"<p><p>Variability characterizes breathing, cellular respiration, and the underlying quantum effects. Variability serves as a mechanism for coping with changing environments; however, this hypothesis does not explain why many of the variable phenomena of respiration manifest randomness. According to the constrained disorder principle (CDP), living organisms are defined by their inherent disorder bounded by variable boundaries. The present paper describes the mechanisms of breathing and cellular respiration, focusing on their inherent variability. It defines how the CDP accounts for the variability and randomness in breathing and respiration. It also provides a scheme for the potential role of respiration variability in the energy balance in biological systems. The paper describes the option of using CDP-based artificial intelligence platforms to augment the respiratory process's efficiency, correct malfunctions, and treat disorders associated with the respiratory system.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 5","pages":"350-367"},"PeriodicalIF":1.8,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41094692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Clinical Significance of Aspergillus Detected in Lower-Respiratory-Tract Samples of Critically Ill COVID-19-Positive Patients. 危重COVID-19阳性患者下呼吸道样本中曲霉菌检测的临床意义。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-09-02 DOI: 10.3390/arm91050027
Heba Osman, Asra N Shaik, Paul L Nguyen, Zachary Cantor, Mirna Kaafarani, Ayman O Soubani

Objective: Critically ill patients with acute respiratory distress syndrome (ARDS) due to viral infection are at risk for secondary complications, including invasive aspergillosis. Our study aimed to characterize the clinical significance and outcome of Aspergillus species isolated from lower-respiratory-tract samples of critically ill OVID-19 patients at a single center. Design: We conducted a retrospective cohort study to evaluate the characteristics of patients with COVID-19 and aspergillus isolated from the lower respiratory tract and to identify predictors of outcomes in this population. Setting: The setting was a single-center hospital system within the metropolitan Detroit region. Results: The prevalence of Aspergillus isolated in hospitalized COVID-19 patients was 1.18% (30/2461 patients), and it was 4.6% in critically ill ICU patients with COVID-19. Probable COVID-19-associated invasive pulmonary aspergillosis (CAPA) was found in 21 critically ill patients, and 9 cases were classified as colonization. The in-hospital mortality of critically ill patients with CAPA and those with aspergillus colonization were high but not significantly different (76% vs. 67%, p = 1.00). Furthermore, the in-hospital mortality for ICU patients with or without Aspergillus isolated was not significantly different 73.3% vs. 64.5%, respectively (OR 1.53, CI 0.64-4.06, p = 0.43). In patients in whom Aspergillus was isolated, antifungal therapy (p = 0.035, OR 12.3, CI 1.74-252); vasopressors (0.016, OR 10.6, CI 1.75-81.8); and a higher mSOFA score (p = 0.043, OR 1.29 CI 1.03-1.72) were associated with a worse outcome. In a multivariable model adjusting for other significant variables, FiO2 was the only variable associated with in-hospital mortality in patients in whom Aspergillus was isolated (OR 1.07, 95% CI 1.01-1.27). Conclusions: The isolation of Aspergillus from lower-respiratory-tract samples of critically ill patients with COVID-19 is associated with high mortality. It is important to have a low threshold for superimposed infections such as CAPA in critically ill patients with COVID-19.

目的:由病毒感染引起的急性呼吸窘迫综合征(ARDS)危重患者有继发并发症的风险,包括侵袭性曲霉菌病。我们的研究旨在描述在一个中心从危重OVID-19患者的下呼吸道样本中分离出的曲霉属物种的临床意义和结果。设计:我们进行了一项回顾性队列研究,以评估新冠肺炎和下呼吸道分离曲霉菌患者的特征,并确定该人群的预后预测因素。环境:该环境是底特律大都市地区的一个单中心医院系统。结果:新冠肺炎住院患者分离曲霉的患病率为1.18%(30/2461例),新冠肺炎重症监护室患者分离曲霉患病率为4.6%。在21例危重患者中发现了可能的COVID-19相关侵袭性肺曲膜炎(CAPA),9例被归类为定植。CAPA危重患者和曲霉菌定植患者的住院死亡率很高,但没有显著差异(76%对67%,p=0.00)。此外,分离或不分离曲霉菌的ICU患者的住院死亡也没有显著差异73.3%对64.5%,在分离出曲霉菌的患者中,抗真菌治疗(p=0.035,OR 12.3,CI 1.74-252);血管升压药(0.016,OR 10.6,CI 1.75-81.8);mSOFA评分越高(p=0.043或1.29 CI 1.03-1.72)与预后越差相关。在一个调整其他显著变量的多变量模型中,FiO2是分离出曲霉菌的患者中唯一与住院死亡率相关的变量(OR 1.07,95%CI 1.01-1.27)。结论:从新冠肺炎危重患者的下呼吸道样本中分离曲霉菌与高死亡率相关。新冠肺炎危重患者的叠加感染(如CAPA)阈值较低是很重要的。
{"title":"The Clinical Significance of Aspergillus Detected in Lower-Respiratory-Tract Samples of Critically Ill COVID-19-Positive Patients.","authors":"Heba Osman,&nbsp;Asra N Shaik,&nbsp;Paul L Nguyen,&nbsp;Zachary Cantor,&nbsp;Mirna Kaafarani,&nbsp;Ayman O Soubani","doi":"10.3390/arm91050027","DOIUrl":"https://doi.org/10.3390/arm91050027","url":null,"abstract":"<p><p><b>Objective</b>: Critically ill patients with acute respiratory distress syndrome (ARDS) due to viral infection are at risk for secondary complications, including invasive aspergillosis. Our study aimed to characterize the clinical significance and outcome of <i>Aspergillus</i> species isolated from lower-respiratory-tract samples of critically ill OVID-19 patients at a single center. <b>Design</b>: We conducted a retrospective cohort study to evaluate the characteristics of patients with COVID-19 and <i>aspergillus</i> isolated from the lower respiratory tract and to identify predictors of outcomes in this population. <b>Setting</b>: The setting was a single-center hospital system within the metropolitan Detroit region. <b>Results</b>: The prevalence of <i>Aspergillus</i> isolated in hospitalized COVID-19 patients was 1.18% (30/2461 patients), and it was 4.6% in critically ill ICU patients with COVID-19. Probable COVID-19-associated invasive pulmonary aspergillosis (CAPA) was found in 21 critically ill patients, and 9 cases were classified as colonization. The in-hospital mortality of critically ill patients with CAPA and those with <i>aspergillus</i> colonization were high but not significantly different (76% vs. 67%, <i>p</i> = 1.00). Furthermore, the in-hospital mortality for ICU patients with or without <i>Aspergillus</i> isolated was not significantly different 73.3% vs. 64.5%, respectively (OR 1.53, CI 0.64-4.06, <i>p</i> = 0.43). In patients in whom <i>Aspergillus</i> was isolated, antifungal therapy (<i>p</i> = 0.035, OR 12.3, CI 1.74-252); vasopressors (0.016, OR 10.6, CI 1.75-81.8); and a higher mSOFA score (<i>p</i> = 0.043, OR 1.29 CI 1.03-1.72) were associated with a worse outcome. In a multivariable model adjusting for other significant variables, FiO<sub>2</sub> was the only variable associated with in-hospital mortality in patients in whom <i>Aspergillus</i> was isolated (OR 1.07, 95% CI 1.01-1.27). <b>Conclusions</b>: The isolation of <i>Aspergillus</i> from lower-respiratory-tract samples of critically ill patients with COVID-19 is associated with high mortality. It is important to have a low threshold for superimposed infections such as CAPA in critically ill patients with COVID-19.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 5","pages":"337-349"},"PeriodicalIF":1.8,"publicationDate":"2023-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41093990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefits from Incorporating Virtual Reality in Pulmonary Rehabilitation of COPD Patients: A Systematic Review and Meta-Analysis. 将虚拟现实技术应用于慢性阻塞性肺病患者的肺康复治疗中的益处:系统回顾与元分析》。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-08-10 DOI: 10.3390/arm91040026
Irini Patsaki, Vasiliki Avgeri, Theodora Rigoulia, Theodoros Zekis, George A Koumantakis, Eirini Grammatopoulou

Chronic Obstructive Pulmonary Disease (COPD) is characterized by irreversible airflow limitation. Patient participation in Pulmonary Rehabilitation (PR) programs has a beneficial effect on disease management, improving patients' functional capacity and quality of life. As an alternative to traditional programs or as a complementary activity, the inclusion of virtual reality (VR) games is proposed. The aim of this research study was to investigate the effectiveness of incorporating VR in the pulmonary rehabilitation program of patients with COPD. A systematic literature search was performed for randomized controlled trials (RCTs) in the electronic databases Google Scholar, PubMed, and Pedro from January 2014 to March 2022. The search involved screening for studies examining the effectiveness of enhancing PR with VR. The PEDro (Physiotherapy Evidence Database) scale was chosen as the tool to assess the quality of studies. A meta-analysis was performed where possible. Six studies were included in this systematic review. The PEDro scale showed five studies of good methodological quality and one of fair quality. The variables examined were: aerobic capacity for exercise, lung function, anxiety and depression, with non-significant improvement for the MRC Dyspnea scale, marginally non-significant improvement regarding 6MWT (p = 0.05) and significant improvement for FEV1 (p < 0.05). There was variability noted in the VR applications and the proposed rehabilitation that the experimental groups followed. The application of VR is recommended for COPD patients, in combination with conventional PR. VR was found to be effective in increasing therapeutic effect and should be considered as a mean of increasing accessibility to PR. Therefore, further research, as well as additional RCTs regarding the effectiveness of VR in patients with COPD, seems necessary.

慢性阻塞性肺病(COPD)的特点是不可逆转的气流受限。患者参与肺康复(PR)项目对疾病管理、提高患者的功能能力和生活质量都有好处。作为传统项目的替代方案或补充活动,建议加入虚拟现实(VR)游戏。本研究旨在探讨将 VR 纳入慢性阻塞性肺病患者肺康复计划的有效性。2014年1月至2022年3月期间,我们在电子数据库谷歌学术、PubMed和Pedro中对随机对照试验(RCT)进行了系统性文献检索。该检索包括筛选考察通过 VR 增强康复效果的研究。选择了物理治疗证据数据库(PEDro)量表作为评估研究质量的工具。在可能的情况下进行荟萃分析。本系统综述共纳入了六项研究。PEDro 量表显示,五项研究的方法质量良好,一项质量一般。研究的变量包括:有氧运动能力、肺功能、焦虑和抑郁,其中 MRC 呼吸困难量表的改善不显著,6MWT 的改善略微不显著(p = 0.05),FEV1 的改善显著(p < 0.05)。实验组在应用 VR 和建议的康复治疗方面存在差异。建议慢性阻塞性肺病患者结合传统的康复治疗应用 VR。研究发现,VR 能有效提高治疗效果,应被视为提高 PR 可及性的一种手段。因此,似乎有必要就 VR 对慢性阻塞性肺病患者的疗效开展进一步研究,并进行更多的 RCT 研究。
{"title":"Benefits from Incorporating Virtual Reality in Pulmonary Rehabilitation of COPD Patients: A Systematic Review and Meta-Analysis.","authors":"Irini Patsaki, Vasiliki Avgeri, Theodora Rigoulia, Theodoros Zekis, George A Koumantakis, Eirini Grammatopoulou","doi":"10.3390/arm91040026","DOIUrl":"10.3390/arm91040026","url":null,"abstract":"<p><p>Chronic Obstructive Pulmonary Disease (COPD) is characterized by irreversible airflow limitation. Patient participation in Pulmonary Rehabilitation (PR) programs has a beneficial effect on disease management, improving patients' functional capacity and quality of life. As an alternative to traditional programs or as a complementary activity, the inclusion of virtual reality (VR) games is proposed. The aim of this research study was to investigate the effectiveness of incorporating VR in the pulmonary rehabilitation program of patients with COPD. A systematic literature search was performed for randomized controlled trials (RCTs) in the electronic databases Google Scholar, PubMed, and Pedro from January 2014 to March 2022. The search involved screening for studies examining the effectiveness of enhancing PR with VR. The PEDro (Physiotherapy Evidence Database) scale was chosen as the tool to assess the quality of studies. A meta-analysis was performed where possible. Six studies were included in this systematic review. The PEDro scale showed five studies of good methodological quality and one of fair quality. The variables examined were: aerobic capacity for exercise, lung function, anxiety and depression, with non-significant improvement for the MRC Dyspnea scale, marginally non-significant improvement regarding 6MWT (p = 0.05) and significant improvement for FEV1 (p < 0.05). There was variability noted in the VR applications and the proposed rehabilitation that the experimental groups followed. The application of VR is recommended for COPD patients, in combination with conventional PR. VR was found to be effective in increasing therapeutic effect and should be considered as a mean of increasing accessibility to PR. Therefore, further research, as well as additional RCTs regarding the effectiveness of VR in patients with COPD, seems necessary.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 4","pages":"324-336"},"PeriodicalIF":1.8,"publicationDate":"2023-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10110382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Machine Learning-Based Model to Predict In-Hospital Mortality of Lung Cancer Patients: A Population-Based Study of 523,959 Cases. 基于机器学习的模型预测肺癌患者住院死亡率:一项基于人群的523,959例研究
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-08-09 DOI: 10.3390/arm91040025
Que N N Tran, Minh-Khang Le, Tetsuo Kondo, Takeshi Moriguchi

Background: Stratify new lung cancer patients based on the risk of in-hospital mortality rate after diagnosis. Methods: 522,941 lung cancer cases with available data on the Surveillance, Epidemiology, and End Results (SEER) were analyzed for the predicted probability based on six fundamental variables including age, gender, tumor size, T, N, and AJCC stages. The patients were randomly assigned to the training (n = 115,145) and validation datasets (n = 13,017). The remaining cohort with missing values (n = 394,779) was then combined with the primary lung tumour datasets (n = 1018) from The Cancer Genome Atlas, Lung Adenocarcinoma and Lung Squamous Cell Carcinoma projects (TCGA-LUAD & TCGA-LUSC) for external validation and sensitivity analysis. Results: Receiver Operating Characteristic (ROC) analyses showed high discriminatory power in the training and internal validation cohorts (Area under the curve [AUC] of 0.78 (95%CI = 0.78-0.79) and 0.78 (95%CI = 0.77-0.79), respectively), whereas that of the model on external validation data was 0.759 (95%CI = 0.757-0.761). We developed a static nomogram, a web app, and a risk table based on a logistic regression model using algorithm-selected variables. Conclusions: Our model can stratify lung cancer patients into high- and low-risk of in-hospital mortality to assist clinical further planning.

背景:基于诊断后住院死亡率的风险对新发肺癌患者进行分层。方法:根据年龄、性别、肿瘤大小、T、N和AJCC分期等6个基本变量,对522941例肺癌患者的监测、流行病学和最终结果(SEER)数据进行预测概率分析。患者被随机分配到训练数据集(n = 115145)和验证数据集(n = 13017)。然后将缺失值的剩余队列(n = 394,779)与来自癌症基因组图谱、肺腺癌和肺鳞状细胞癌项目(TCGA-LUAD和TCGA-LUSC)的原发性肺肿瘤数据集(n = 1018)相结合,进行外部验证和敏感性分析。结果:受试者工作特征(Receiver Operating Characteristic, ROC)分析显示,训练组和内部验证组的鉴别力较高(曲线下面积(Area under the curve, AUC)分别为0.78 (95%CI = 0.78-0.79)和0.78 (95%CI = 0.77-0.79),而外部验证组的鉴别力为0.759 (95%CI = 0.757-0.761)。我们开发了一个静态nomogram,一个web app,以及一个基于逻辑回归模型的风险表,该模型使用算法选择变量。结论:我们的模型可以将肺癌患者分为院内死亡率的高风险和低风险,以帮助临床进一步规划。
{"title":"A Machine Learning-Based Model to Predict In-Hospital Mortality of Lung Cancer Patients: A Population-Based Study of 523,959 Cases.","authors":"Que N N Tran,&nbsp;Minh-Khang Le,&nbsp;Tetsuo Kondo,&nbsp;Takeshi Moriguchi","doi":"10.3390/arm91040025","DOIUrl":"https://doi.org/10.3390/arm91040025","url":null,"abstract":"<p><p><b>Background:</b> Stratify new lung cancer patients based on the risk of in-hospital mortality rate after diagnosis. <b>Methods:</b> 522,941 lung cancer cases with available data on the Surveillance, Epidemiology, and End Results (SEER) were analyzed for the predicted probability based on six fundamental variables including age, gender, tumor size, T, N, and AJCC stages. The patients were randomly assigned to the training (<i>n</i> = 115,145) and validation datasets (<i>n</i> = 13,017). The remaining cohort with missing values (<i>n</i> = 394,779) was then combined with the primary lung tumour datasets (<i>n</i> = 1018) from The Cancer Genome Atlas, Lung Adenocarcinoma and Lung Squamous Cell Carcinoma projects (TCGA-LUAD & TCGA-LUSC) for external validation and sensitivity analysis. <b>Results:</b> Receiver Operating Characteristic (ROC) analyses showed high discriminatory power in the training and internal validation cohorts (Area under the curve [AUC] of 0.78 (95%CI = 0.78-0.79) and 0.78 (95%CI = 0.77-0.79), respectively), whereas that of the model on external validation data was 0.759 (95%CI = 0.757-0.761). We developed a static nomogram, a web app, and a risk table based on a logistic regression model using algorithm-selected variables. <b>Conclusions:</b> Our model can stratify lung cancer patients into high- and low-risk of in-hospital mortality to assist clinical further planning.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 4","pages":"310-323"},"PeriodicalIF":1.8,"publicationDate":"2023-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10455605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Volatile Organic Compound Identification-Based Tuberculosis Screening among TB Suspects: A Diagnostic Accuracy Study. 基于挥发性有机化合物鉴定的结核病疑似患者筛查:诊断准确性研究
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-07-12 DOI: 10.3390/arm91040024
Mayank Badola, Anurag Agrawal, Debabrata Roy, Richa Sinha, Avisham Goyal, Narayan Jeet

Tuberculosis (TB) affects a third of the global population, and a large population of infected individuals still remain undiagnosed-making the visible burden only the tip of the iceberg. The detection of tuberculosis in close-proximity patients is one of the key priorities for attaining the Sustainable Development Goals (SDG) of TB elimination by 2030. With the current battery of screening tests failing to cover this need, the authors of this paper examined a simple and inexpensive point-of-care breath analyzer (TSI-3000(I)), which is based on detecting the volatile organic compounds that are emitted from infected cells and released in exhaled breath as a screening tool for the detection of TB. A single-center pilot study for assessing the diagnostic accuracy of the point-of-care Tuberculosis Breath Analyzer was conducted, and it was compared against the WHO-recommended TrueNat assay, which is a rapid molecular test and was also treated as the reference standard in this study. Of the 334 enrolled participants with TB signs/symptoms, 42.51% were TrueNat positive for Mycobacterium tuberculosis. The sensitivity of the Tuberculosis Breath Analyzer was found to be 95.7%, with a specificity of 91.3% and a ROC area of 0.935. The test kit showed considerable/significant high sensitivity and specificity as reliability indicators. The performance of the Tuberculosis Breath Analyzer tested was found to be comparable in efficiency to that of the TrueNat assay. A large cohort-based multicentric study is feasibly required to further validate and extrapolate the results of the pilot study.

结核病影响着全球三分之一的人口,而且大量感染者仍未得到诊断——可见的负担只是冰山一角。在近距离患者中检测结核病是实现到2030年消除结核病的可持续发展目标的关键优先事项之一。由于目前的一系列筛查测试无法满足这一需求,本文的作者研究了一种简单而廉价的即时呼吸分析仪(TSI-3000(I)),它基于检测从受感染细胞释放并在呼出的气体中释放的挥发性有机化合物,作为检测结核病的筛查工具。开展了一项评估即时护理结核呼吸分析仪诊断准确性的单中心试点研究,并将其与世卫组织推荐的快速分子检测方法TrueNat进行了比较,TrueNat也是本研究的参考标准。在334名有结核病体征/症状的参与者中,42.51%的人结核分枝杆菌TrueNat阳性。结核呼吸分析仪的灵敏度为95.7%,特异度为91.3%,ROC面积为0.935。该试剂盒作为可靠性指标具有相当高的灵敏度和特异性。肺结核呼吸分析仪测试的性能被发现与TrueNat测定的效率相当。可能需要一项大型的基于队列的多中心研究来进一步验证和推断初步研究的结果。
{"title":"Volatile Organic Compound Identification-Based Tuberculosis Screening among TB Suspects: A Diagnostic Accuracy Study.","authors":"Mayank Badola,&nbsp;Anurag Agrawal,&nbsp;Debabrata Roy,&nbsp;Richa Sinha,&nbsp;Avisham Goyal,&nbsp;Narayan Jeet","doi":"10.3390/arm91040024","DOIUrl":"https://doi.org/10.3390/arm91040024","url":null,"abstract":"<p><p>Tuberculosis (TB) affects a third of the global population, and a large population of infected individuals still remain undiagnosed-making the visible burden only the tip of the iceberg. The detection of tuberculosis in close-proximity patients is one of the key priorities for attaining the Sustainable Development Goals (SDG) of TB elimination by 2030. With the current battery of screening tests failing to cover this need, the authors of this paper examined a simple and inexpensive point-of-care breath analyzer (TSI-3000(I)), which is based on detecting the volatile organic compounds that are emitted from infected cells and released in exhaled breath as a screening tool for the detection of TB. A single-center pilot study for assessing the diagnostic accuracy of the point-of-care Tuberculosis Breath Analyzer was conducted, and it was compared against the WHO-recommended TrueNat assay, which is a rapid molecular test and was also treated as the reference standard in this study. Of the 334 enrolled participants with TB signs/symptoms, 42.51% were TrueNat positive for Mycobacterium tuberculosis. The sensitivity of the Tuberculosis Breath Analyzer was found to be 95.7%, with a specificity of 91.3% and a ROC area of 0.935. The test kit showed considerable/significant high sensitivity and specificity as reliability indicators. The performance of the Tuberculosis Breath Analyzer tested was found to be comparable in efficiency to that of the TrueNat assay. A large cohort-based multicentric study is feasibly required to further validate and extrapolate the results of the pilot study.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 4","pages":"301-309"},"PeriodicalIF":1.8,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9865521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma. 开放和封闭三联吸入器治疗未控制哮喘患者。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-07-04 DOI: 10.3390/arm91040023
Serafeim-Chrysovalantis Kotoulas, Ioanna Tsiouprou, Kalliopi Domvri, Polyxeni Ntontsi, Athanasia Pataka, Konstantinos Porpodis

Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting β2-agonists (ICS + LABA) (closed triple inhaler therapy) or in a separate one (open triple inhaler therapy). This review summarizes the existing evidence on the addition of LAMAs in patients with persistently uncontrolled asthma despite ICS + LABA treatment based on clinical efficacy in the reduction of asthma symptoms and exacerbations, the improvement in lung function, and its safety profile.

长效毒蕈碱拮抗剂(LAMAs)是一类最近被纳入GINA指南的附加治疗的吸入器,无论是在吸入皮质类固醇加长效β2激动剂(ICS + LABA)的单一吸入器装置中(闭式三联吸入器治疗)还是在单独的吸入器中(开放式三联吸入器治疗)。本文综述了在ICS + LABA治疗后持续不受控制的哮喘患者中添加LAMAs的现有证据,包括在减轻哮喘症状和加重、改善肺功能和安全性方面的临床疗效。
{"title":"Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma.","authors":"Serafeim-Chrysovalantis Kotoulas,&nbsp;Ioanna Tsiouprou,&nbsp;Kalliopi Domvri,&nbsp;Polyxeni Ntontsi,&nbsp;Athanasia Pataka,&nbsp;Konstantinos Porpodis","doi":"10.3390/arm91040023","DOIUrl":"https://doi.org/10.3390/arm91040023","url":null,"abstract":"<p><p>Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting β2-agonists (ICS + LABA) (closed triple inhaler therapy) or in a separate one (open triple inhaler therapy). This review summarizes the existing evidence on the addition of LAMAs in patients with persistently uncontrolled asthma despite ICS + LABA treatment based on clinical efficacy in the reduction of asthma symptoms and exacerbations, the improvement in lung function, and its safety profile.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 4","pages":"288-300"},"PeriodicalIF":1.8,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9865517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Application and Technical Principles of Catheter High-Frequency Jet Ventilation. 导管高频射流通气的应用及技术原理。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-06-27 DOI: 10.3390/arm91040022
Peter Musil, Stefan Harsanyi, Pavol Torok, Monika Paulikova, Didier Moens, Ladislav Kalas, Peter Kalas

The aim of this publication is to analyze the topic of high-frequency jet ventilation (HFJV), namely catheter HFJV (C-HFJV), from a mathematical-physical as well as a clinical point of view. There are known issues with applying anesthesia and artificial lung ventilation (ALV) during surgical procedures in the upper airways, e.g., during bronchoscopy or tracheostomy. The principles, advantages, and disadvantages of HFJV are discussed in context with basic physical principles to clarify the proper use of this method. The basic technical principles of catheter construction, as well as its functional properties from a biophysical point of view, are introduced. Also, the placement of the catheter in the airways, the set-up of the HFJV ventilator, and the indications as well as the risks and contraindications of the use of C-HFJV are analyzed. This leads to the explanation of potentially optimal techniques for C-HFJV applications. In this article, we present the positive effects of C-HFJV even with complications such as bacterial or viral pneumonia, including COVID-19. In conclusion, we offer recommendations for clinical practice obtained from a literature review and from our rich clinical experience.

本出版物的目的是分析高频喷射通气(HFJV)的主题,即导管HFJV (C-HFJV),从数学物理和临床的角度来看。在上气道手术过程中,例如在支气管镜检查或气管切开术中,应用麻醉和人工肺通气(ALV)存在已知的问题。在基本物理原理的背景下讨论了HFJV的原理、优点和缺点,以阐明该方法的正确使用。介绍了导管结构的基本技术原理,以及从生物物理学的角度介绍了导管的功能特性。分析了导管在气道内的放置、HFJV呼吸机的设置、C-HFJV的适应症以及使用的风险和禁忌症。这就解释了C-HFJV应用的潜在最佳技术。在本文中,我们介绍了C-HFJV的积极作用,即使有并发症,如细菌性或病毒性肺炎,包括COVID-19。综上所述,我们从文献综述和丰富的临床经验中提出临床实践建议。
{"title":"Application and Technical Principles of Catheter High-Frequency Jet Ventilation.","authors":"Peter Musil,&nbsp;Stefan Harsanyi,&nbsp;Pavol Torok,&nbsp;Monika Paulikova,&nbsp;Didier Moens,&nbsp;Ladislav Kalas,&nbsp;Peter Kalas","doi":"10.3390/arm91040022","DOIUrl":"https://doi.org/10.3390/arm91040022","url":null,"abstract":"<p><p>The aim of this publication is to analyze the topic of high-frequency jet ventilation (HFJV), namely catheter HFJV (C-HFJV), from a mathematical-physical as well as a clinical point of view. There are known issues with applying anesthesia and artificial lung ventilation (ALV) during surgical procedures in the upper airways, e.g., during bronchoscopy or tracheostomy. The principles, advantages, and disadvantages of HFJV are discussed in context with basic physical principles to clarify the proper use of this method. The basic technical principles of catheter construction, as well as its functional properties from a biophysical point of view, are introduced. Also, the placement of the catheter in the airways, the set-up of the HFJV ventilator, and the indications as well as the risks and contraindications of the use of C-HFJV are analyzed. This leads to the explanation of potentially optimal techniques for C-HFJV applications. In this article, we present the positive effects of C-HFJV even with complications such as bacterial or viral pneumonia, including COVID-19. In conclusion, we offer recommendations for clinical practice obtained from a literature review and from our rich clinical experience.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 4","pages":"278-287"},"PeriodicalIF":1.8,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9865520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single Nucleotide Polymorphisms of FAM13A Gene in Chronic Obstructive Pulmonary Disease-A Case Control Study in Vietnam. 慢性阻塞性肺疾病FAM13A基因的单核苷酸多态性——越南病例对照研究
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-06-15 DOI: 10.3390/arm91030021
Khanh Hoang Pham, Nhung Thi Cam Tran, Hung Do Tran, Toan Hoang Ngo, Van De Tran, Hung Huynh Vinh Ly, Nga Thi Ngoc Pham, Thang Nguyen, Binh Huy Nguyen, Kien Trung Nguyen

Background: In 2018, GOLD addressed the issues of genotypes associated with risk factors for COPD. The genome-wide association study (GWAS) demonstrated an association between COPD and several genetic variants of single nucleotide polymorphisms (SNPs) of the FAM13A gene with the risk of COPD.

Objective: To study the single nucleotide polymorphisms rs2869967 and rs17014601 of the FAM13A gene in chronic obstructive pulmonary disease. Subjects and research methods: 80 subjects diagnosed with COPD and 80 subjects determined not to have COPD according to GOLD 2020 criteria; the subjects were clinically examined, interviewed, and identified as possessing single nucleotide polymorphisms using the sanger sequencing method on whole blood samples.

Results: The male/female ratio of the patient group and the control group was 79/1 and 39/1, respectively. The percentages of C and T alleles of rs2869967 in COPD patients were 50.6% and 49.4%, respectively. The percentages of C and T alleles of rs17014601 in COPD patients were 31.9% and 68.1%, respectively. At rs17014601, the ratio values of alleles T and C in the disease group and the control group were markedly different, making them statistically reliable (p = 0.031). The rate of CT genotype in the group of patients was considerably higher than that of the control group. The TT homozygous genotype had a lower risk of COPD compared with the other genotypes in the dominant model (ORTT/(CC + CT) = 0.441; CI95% = 0.233-0.833); this difference was statistically significant (p = 0.012).

Conclusions: With rs17014601, it is characteristic that the frequency of the T allele appears more than the C allele, and the CT heterozygous phenotype accounts for the highest proportion in rs17014601 and rs2869967 recorded in COPD patients. There is an association between the genetic variant of the SNP FAM13A-rs17014601 and the risk of COPD.

背景:2018年,GOLD研究了与COPD危险因素相关的基因型问题。全基因组关联研究(GWAS)表明,慢性阻塞性肺病与FAM13A基因单核苷酸多态性(snp)的几种遗传变异与慢性阻塞性肺病风险之间存在关联。目的:研究慢性阻塞性肺疾病FAM13A基因rs2869967和rs17014601的单核苷酸多态性。受试者和研究方法:80名诊断为COPD的受试者和80名根据GOLD 2020标准确定不患有COPD的受试者;对受试者进行临床检查、访谈,并使用全血样本的sanger测序方法确定其具有单核苷酸多态性。结果:患者组和对照组的男女比例分别为79/1和39/1。rs2869967等位基因C和T在COPD患者中的比例分别为50.6%和49.4%。rs17014601的C和T等位基因在COPD患者中的比例分别为31.9%和68.1%。在rs17014601位点,疾病组与对照组等位基因T、C比值值差异有统计学意义(p = 0.031)。患者组CT基因型检出率明显高于对照组。在优势模型中,TT纯合子基因型患COPD的风险较其他基因型低(ORTT/(CC + CT) = 0.441;(95% = 0.233-0.833);差异有统计学意义(p = 0.012)。结论:rs17014601具有T等位基因出现频率高于C等位基因的特点,且CT杂合表型在COPD患者记录的rs17014601和rs2869967中所占比例最高。SNP FAM13A-rs17014601的遗传变异与COPD风险之间存在关联。
{"title":"Single Nucleotide Polymorphisms of <i>FAM13A</i> Gene in Chronic Obstructive Pulmonary Disease-A Case Control Study in Vietnam.","authors":"Khanh Hoang Pham,&nbsp;Nhung Thi Cam Tran,&nbsp;Hung Do Tran,&nbsp;Toan Hoang Ngo,&nbsp;Van De Tran,&nbsp;Hung Huynh Vinh Ly,&nbsp;Nga Thi Ngoc Pham,&nbsp;Thang Nguyen,&nbsp;Binh Huy Nguyen,&nbsp;Kien Trung Nguyen","doi":"10.3390/arm91030021","DOIUrl":"https://doi.org/10.3390/arm91030021","url":null,"abstract":"<p><strong>Background: </strong>In 2018, GOLD addressed the issues of genotypes associated with risk factors for COPD. The genome-wide association study (GWAS) demonstrated an association between COPD and several genetic variants of single nucleotide polymorphisms (SNPs) of the <i>FAM13A</i> gene with the risk of COPD.</p><p><strong>Objective: </strong>To study the single nucleotide polymorphisms rs2869967 and rs17014601 of the <i>FAM13A</i> gene in chronic obstructive pulmonary disease. Subjects and research methods: 80 subjects diagnosed with COPD and 80 subjects determined not to have COPD according to GOLD 2020 criteria; the subjects were clinically examined, interviewed, and identified as possessing single nucleotide polymorphisms using the sanger sequencing method on whole blood samples.</p><p><strong>Results: </strong>The male/female ratio of the patient group and the control group was 79/1 and 39/1, respectively. The percentages of C and T alleles of rs2869967 in COPD patients were 50.6% and 49.4%, respectively. The percentages of C and T alleles of rs17014601 in COPD patients were 31.9% and 68.1%, respectively. At rs17014601, the ratio values of alleles T and C in the disease group and the control group were markedly different, making them statistically reliable (<i>p</i> = 0.031). The rate of CT genotype in the group of patients was considerably higher than that of the control group. The TT homozygous genotype had a lower risk of COPD compared with the other genotypes in the dominant model (ORTT/(CC + CT) = 0.441; CI95% = 0.233-0.833); this difference was statistically significant (<i>p</i> = 0.012).</p><p><strong>Conclusions: </strong>With rs17014601, it is characteristic that the frequency of the T allele appears more than the C allele, and the CT heterozygous phenotype accounts for the highest proportion in rs17014601 and rs2869967 recorded in COPD patients. There is an association between the genetic variant of the SNP <i>FAM13A</i>-rs17014601 and the risk of COPD.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 3","pages":"268-277"},"PeriodicalIF":1.8,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9773284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Pharmacist-Led Interventions on Medication Adherence among Vietnamese Patients with Asthma: A Randomized Controlled Trial. 药师主导的干预措施对越南哮喘患者服药依从性的影响:一项随机对照试验。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-06-13 DOI: 10.3390/arm91030020
Tan Thanh Nguyen, Mai Thi Xuan Truong, Dung Ngoc Lam, Tuyen Thi Thanh Le, Mai Tuyet Vi, Thanh My Tran, Thu Pham Minh Vo, Suol Thanh Pham, Bao Lam Thai Tran, Thang Nguyen, Lam Van Nguyen

Background: Medication adherence in asthmatic patients enhances the effectiveness of treatments, but some studies in low and middle-income countries still show some limitations. Our study aimed to determine if pharmacist-led interventions could increase medication adherence, improve treatment effectiveness, and relieve symptom severity in outpatients with asthma.

Methods: We conducted a randomized, controlled trial on 247 asthmatic outpatients (aged ≥ 16) with a 1:1 ratio randomization at the hospitalization time and repeated after 1-month discharge. The primary outcome was to detect the difference in medication adherence between groups. Adherence was assessed by the general medication adherence scale (GMAS). Data collected by questionnaire was coded and entered into SPSS_20 for statistical analysis; Results: 247 patients (123 intervention, 124 control) were enrolled (61.1% male). After intervention, the adherence rate was higher among the intervention group than the control group (94.3% vs. 82.8%, p = 0.001). Patient behavior and knowledge were enhanced in the intervention group (p < 0.05). Asthma symptoms were relieved in the intervention group (p = 0.014). Pharmacist-led interventions on adherence rate were higher with OR: 3.550, 95% CI: 1.378-9.143, p = 0.009.

Conclusions: pharmaceutical intervention could improve medication adherence, treatment efficacy, and the outcome should not be taken for granted; further research should be carried out in this regard.

背景:哮喘患者的药物依从性提高了治疗的有效性,但在低收入和中等收入国家的一些研究仍然显示出一些局限性。我们的研究旨在确定药剂师主导的干预措施是否可以增加哮喘门诊患者的药物依从性,提高治疗效果,缓解症状严重程度。方法:对247例年龄≥16岁的哮喘门诊患者进行随机对照试验,住院时按1:1比例随机,出院后1个月重复。主要结果是检测组间药物依从性的差异。采用一般药物依从性量表(GMAS)评估依从性。对问卷收集的数据进行编码,录入SPSS_20进行统计分析;结果:纳入247例患者(干预组123例,对照组124例),其中男性61.1%。干预后,干预组依从率高于对照组(94.3% vs. 82.8%, p = 0.001)。干预组患者的行为和知识均有所提高(p < 0.05)。干预组哮喘症状明显缓解(p = 0.014)。药师主导干预对依从率的影响较高,OR: 3.550, 95% CI: 1.378 ~ 9.143, p = 0.009。结论:药物干预可提高患者的服药依从性和治疗效果,其结果不应想当然;在这方面应进行进一步的研究。
{"title":"Effect of Pharmacist-Led Interventions on Medication Adherence among Vietnamese Patients with Asthma: A Randomized Controlled Trial.","authors":"Tan Thanh Nguyen,&nbsp;Mai Thi Xuan Truong,&nbsp;Dung Ngoc Lam,&nbsp;Tuyen Thi Thanh Le,&nbsp;Mai Tuyet Vi,&nbsp;Thanh My Tran,&nbsp;Thu Pham Minh Vo,&nbsp;Suol Thanh Pham,&nbsp;Bao Lam Thai Tran,&nbsp;Thang Nguyen,&nbsp;Lam Van Nguyen","doi":"10.3390/arm91030020","DOIUrl":"https://doi.org/10.3390/arm91030020","url":null,"abstract":"<p><strong>Background: </strong>Medication adherence in asthmatic patients enhances the effectiveness of treatments, but some studies in low and middle-income countries still show some limitations. Our study aimed to determine if pharmacist-led interventions could increase medication adherence, improve treatment effectiveness, and relieve symptom severity in outpatients with asthma.</p><p><strong>Methods: </strong>We conducted a randomized, controlled trial on 247 asthmatic outpatients (aged ≥ 16) with a 1:1 ratio randomization at the hospitalization time and repeated after 1-month discharge. The primary outcome was to detect the difference in medication adherence between groups. Adherence was assessed by the general medication adherence scale (GMAS). Data collected by questionnaire was coded and entered into SPSS_20 for statistical analysis; Results: 247 patients (123 intervention, 124 control) were enrolled (61.1% male). After intervention, the adherence rate was higher among the intervention group than the control group (94.3% vs. 82.8%, <i>p</i> = 0.001). Patient behavior and knowledge were enhanced in the intervention group (<i>p</i> < 0.05). Asthma symptoms were relieved in the intervention group (<i>p</i> = 0.014). Pharmacist-led interventions on adherence rate were higher with OR: 3.550, 95% CI: 1.378-9.143, <i>p</i> = 0.009.</p><p><strong>Conclusions: </strong>pharmaceutical intervention could improve medication adherence, treatment efficacy, and the outcome should not be taken for granted; further research should be carried out in this regard.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 3","pages":"254-267"},"PeriodicalIF":1.8,"publicationDate":"2023-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10077045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advances in respiratory medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1